Get the Stockscreener App
0.466
12.32%
-0.0655
Pre-market:
.44
-0.026
-5.58%
AEON Biopharma Inc. stock is traded at $0.466, with a volume of 376.65K.
It is down -12.32% in the last 24 hours and down -2.92% over the past month.
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine. AEON Biopharma, Inc. is based in Irvine, California.
See More
Previous Close:
$0.5315
Open:
$0.5264
24h Volume:
376.65K
Relative Volume:
0.13
Market Cap:
$4.91M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-21.42%
1M Performance:
-2.92%
6M Performance:
-99.47%
1Y Performance:
-99.92%
1-Day Range:
$0.4507
$0.5264
1-Week Range:
$0.4507
$0.61
52-Week Range:
$0.412
$619.20
AEON Biopharma Inc. Stock (AEON) Company Profile
Name
AEON Biopharma Inc.
Sector
Industry
Phone
(949) 354-6499
Address
5 Park Plaza, Suite 1750, Irvine
Compare AEON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.466 | 4.91M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-23 | Initiated | H.C. Wainwright | Buy |
AEON Biopharma Inc. Stock (AEON) Latest News
AEON Biopharma’s Strategic Progress and Financial Turnaround - TipRanks
AEON Biopharma announces leadership change amid growth strategy By Investing.com - Investing.com Philippines
Aeon Biopharma CEO to Step Down Next Week - Orange County Business Journal
AEON Biopharma CEO Marc Forth to Resign; Board Chairman Jost Fischer Is Interim CEO - MarketScreener
AEON Biopharma announces leadership change amid growth strategy - Investing.com
AEON Biopharma Announces CEO Resignation and Interim Appointment - TipRanks
AEON Biopharma Announces CEO Transition - The Manila Times
Leadership Shift at AEON Biopharma: CEO Exit Won't Delay Critical FDA Timeline - Stock Titan
AEON Eyeing FDA Meeting On Botox Biosimilar By The End Of 2025 - News & Insights
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
AEON Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma, Inc. Advances Biosimilar Development for ABP-450 with FDA Meeting Planned for 2025 - Nasdaq
AEON's $20M Cash Injection Powers Game-Changing BOTOX Alternative Development - Stock Titan
AEON Biopharma (NASDAQ:AEON) Stock Price Down 7.6% – Should You Sell? - Defense World
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Understanding AEON’s financial ratios: A beginner’s guide - US Post News
AEON Biopharma Releases New Corporate Presentation - TipRanks
AEON Biopharma : Corporate Presentation -March 10, 2025 at 06:26 am EDT - Marketscreener.com
AEON Biopharma, Inc. to Participate in the Leerink Global Healthcare Conference - The Manila Times
AEON CEO to Showcase Botulinum Toxin Pipeline at Major Healthcare Conference - StockTitan
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
Cervical Dystonia Market Expected to Experience Major Growth - openPR
AEON stock touches 52-week low at $0.76 amid market shifts - Investing.com
AEON Biopharma, Inc. Deloitte, Inc. Announces Update of Phase 2 Double Blind Study of ABP-450 in the Treatment of Migraine - Marketscreener.com
AEON Biopharma Announces Preliminary Top-Line Results from Phase 2 Interim Analysis of ABP-450 in the Preventive Treatment of Chronic Migraine -May 03, 2024 at 07:00 am EDT - MarketScreener
AEON Biopharma, Inc. Announces Executive Changes -May 16, 2024 at 04:28 pm EDT - MarketScreener
AEON Biopharma, Inc. Announces Strategic Reprioritization to Pursue A Biosimilar Pathway for ABP-450 - Marketscreener.com
AEON Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - MarketScreener
AEON Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Stock market news: AEON Biopharma plummented by 65.33% while Enveric Biosciences skyrocketed by 90.68% during midday trading - Business Upturn
Stock market today: AEON Biopharma plunged by 63.17% while Enveric Biosciences surged by 124.66% in early trading - Business Upturn
AEON Biopharma To Implement 1-for-72 Reverse Stock Split For Compliance With NYSE Rules - Nasdaq
AEON Biopharma, Inc. Announces Reverse Stock Split - The Manila Times
AEON Biopharma executes reverse stock split to comply with NYSE standards - Investing.com Australia
Aeon Biopharma Approves 1-For-72 Reverse Stock Split -February 24, 2025 at 02:53 pm EST - Marketscreener.com
AEON Biopharma shares plunge as it announces reverse stock split - MSN
AEON Biopharma Stockholders Approve Key Proposals - TipRanks
AEON Biopharma Announces 1-for-72 Reverse Stock Split Effective February 26, 2025 - Nasdaq
Aeon to Implement 1-for-72 Reverse Stock Split; Shares Fall - MarketScreener
AEON Biopharma Inc (AEON) Shares Down Despite Recent Market Volatility - The News Heater
Watch this stock’s price performance: AEON Biopharma Inc (AMEX:AEON) - US Post News
AEON Biopharma Receives Notice Of Non-Compliance With NYSE American Listing Standards - Nasdaq
AEON Biopharma Inc (AMEX: AEON) Could See A Rise In Prices Shortly. - Marketing Sentinel
Investor’s Delight: AEON Biopharma Inc (AEON) Closes Weak at 0.13, Down -6.93 - The Dwinnex
AEON Biopharma receives NYSE non-compliance notice - MSN
AEON Biopharma, Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards - The Manila Times
Aeon Biopharma Gets NYSE American Noncompliance Notice -February 07, 2025 at 05:06 pm EST - Marketscreener.com
Aeon Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards - Marketscreener.com
AEON Biopharma Inc [AEON] Stock trading around $0.14 per share: What’s Next? - The DBT News
AEON Biopharma, Inc. Receives Notice of Non-Compliance from NYSE American Due to Stockholders' Deficit - Nasdaq
AEON Biopharma Inc Inc. (AEON) Price Performance: A Comparative Analysis with Competitors - The InvestChronicle
AEON Biopharma Inc. Stock (AEON) Financials Data
There is no financial data for AEON Biopharma Inc. (AEON). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.01%
Cap:
|
Volume (24h):